Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone
|ClinicalTrials.gov Identifier: NCT00480844|
Recruitment Status : Unknown
Verified March 2009 by Sheba Medical Center.
Recruitment status was: Recruiting
First Posted : May 31, 2007
Last Update Posted : March 25, 2009
In this study we intend to compare the effect of Sertindole to that of Risperidone on cognitive impairment in schizophrenia.
Hypothesis: Sertindole will be as effective as Risperidone for treating cognitive impairment in schizophrenia and with fewer side effects.
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia||Drug: Sertindole Drug: Risperidone||Phase 4|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone|
|Study Start Date :||October 2008|
|Estimated Primary Completion Date :||October 2011|
Oral (tablets), 16-24 mg QD (once a day) for 12 weeks.
Other Name: Serdolect
|Active Comparator: Risperidone||
Oral (tablets), 4-8 mg QD (once a day) for 12 weeks.
- cognitive functioning [ Time Frame: 24 weeks ]
- Discontinuation due to all causes, symptomatology and adverse events. [ Time Frame: 24 weeks ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00480844
|Contact: Mark Weiser, Drfirstname.lastname@example.org|
|Department of Psychiatry of the Sheba Medical Center||Recruiting|
|Ramat Gan, Tel Hashomer, Israel, 52621|
|Contact: Mark Weiser, Dr 03-5303773 email@example.com|
|Principal Investigator: Mark Weiser, Dr|
|Beer-Yaakov Mental Health Center||Not yet recruiting|
|Beer-Yaakov, Israel, 70350|
|Principal Investigator: Yehuda Abramowitz, Dr|
|Kfar Shaul Mental Health Center||Not yet recruiting|
|Jerusalem, Israel, 91060|
|Principal Investigator: Alexander Teitelbaum, Dr|
|Principal Investigator:||Mark Weiser, Dr||Shaba Medical Center, Tel-Aviv University Sackler School of Medicine|